Niki Couper

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

R. Laing, P. Ellis, H. Earl, 2017, The Lancet. Oncology.

A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)

James O. Jones, A. Matakidou, E. Sala, 2022, British Journal of Cancer.